Navigation Links
DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
Date:4/10/2013

titute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor StatementAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit www.delmarpharma.com; or contact

Jeffrey A. Bacha
President & CEO
DelMar Pharmaceuticals
(604) 629-5989

-or-

Booke & Company Investor Relations
admin@bookeandco.com

 


'/>"/>
SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
2. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
3. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
4. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
5. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
6. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
7. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
8. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
9. Global Pharmacy Automation Market 2012-2016 with McKesson Corp., ScriptPro LLC, Parata Systems LLC Dominating
10. Global Pharmaceutical Leader Chooses Acsis Enterprise Serialization Management Suite to Achieve e-Pedigree Compliance
11. Zosano Pharma, Inc. Announces Key Strategic Hire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... --  Clementia Pharmaceuticals, Inc. today announced that ... (Part B) of its natural history study in ... severely disabling congenital myopathy characterized by painful, recurrent ... in the formation of new, abnormal (heterotopic) bone ... The multi-center, non-interventional, two-part longitudinal study is designed ...
(Date:5/28/2015)... SAN DIEGO , May 28, 2015 ... immuno-oncology drug development company, announced today that its President ... present at the LD Micro Invitational Investor Conference ... Bel Air, California on June ... corporate update including highlights from the significant progress made ...
(Date:5/28/2015)... IRVING, Texas , May 28, 2015 /PRNewswire/ ... on fulfilling the promise of precision medicine, today ... cohort studies that demonstrate the utility of Caris ... service, in characterizing mechanisms of drug resistance and ... presented May 31 in poster sessions at the ...
Breaking Medicine Technology:Clementia Advances Natural History Study of Patients with Fibrodysplasia Ossificans Progressiva 2Clementia Advances Natural History Study of Patients with Fibrodysplasia Ossificans Progressiva 3MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT 2MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT 3MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT 4Caris Life Sciences Presents Large Cohort Biomarker Analyses that Characterizes Drug Resistances and Pathway Aberrations to Inform Targeted Anticancer Treatment Strategies 2Caris Life Sciences Presents Large Cohort Biomarker Analyses that Characterizes Drug Resistances and Pathway Aberrations to Inform Targeted Anticancer Treatment Strategies 3Caris Life Sciences Presents Large Cohort Biomarker Analyses that Characterizes Drug Resistances and Pathway Aberrations to Inform Targeted Anticancer Treatment Strategies 4Caris Life Sciences Presents Large Cohort Biomarker Analyses that Characterizes Drug Resistances and Pathway Aberrations to Inform Targeted Anticancer Treatment Strategies 5
... Va. , Feb. 3 CEL-SCI Corporation ... Officer, will be presenting at the 2010 BIO CEO & Investor ... take place February 8-9 at the Waldorf=Astoria in ... Tuesday, February 9th , at 1:30 p.m. EST .  The ...
... , Feb. 3 Repligen Corporation (Nasdaq: RGEN ... from the United States Patent and Trademark Office for a patent ... structure to the commercial form of Protein A from Staphylococcus ... the world,s approved monoclonal antibodies . The patent, which ...
Cached Medicine Technology:CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference 2Repligen Receives Notice of Allowance for Recombinant Protein A Patent 2Repligen Receives Notice of Allowance for Recombinant Protein A Patent 3
(Date:5/28/2015)... Dr. Paul Vitenas, one of the nation’s ... new Houston Surgery Center he recently opened has received ... Surgery Facilities awarded this accreditation to Dr. Vitenas’ new ... Dr. Vitenas, the certificate was given to the surgery ... ambulatory surgery facility. This certification means the Houston Surgery ...
(Date:5/28/2015)... Beverly Hills, CA (PRWEB) May 28, 2015 ... a novel interactive keratoconus web application to ... Keratoconus has expanded in the last few years. This ... Even eye doctors are not aware of the nuances ... the Khanna Vision Institute, realized that websites can be ...
(Date:5/28/2015)... lifeIMAGE announced today that it ... by Cambia Health Solutions (Portland, Ore.), a ... care by creating a person-focused and economically sustainable system. ... exchanging medical imaging, will use this financing to expand ... of its network capabilities and implement the next phases ...
(Date:5/28/2015)... IL (PRWEB) May 28, 2015 Cancer ... program exhibited improvements in physical activity, fitness and quality ... Irwin of Yale Cancer Center and Jennifer Ligibel, MD, ... Women’s Cancers, Dana Farber Cancer Institute. The findings will ... Clinical Oncology (ASCO) Annual Meeting in Chicago. ...
(Date:5/28/2015)... May 28, 2015 Ask not what your ... things you can do with your racquet. With the launch ... Stefan Bojic, who brings his astonishing tricks and unique skill ... a series of videos, the trick artist playfully demonstrates how ... skills in a fun way, but also challenges tennis enthusiasts ...
Breaking Medicine News(10 mins):Health News:Dr. Paul Vitenas’ New Houston Surgery Center Receives AAAASF Accreditation 2Health News:Dr.Khanna Announced the Release of an Interactive Web Application for Keratoconus Treatment 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 4Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 2Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 3Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 4Health News:Tennis Artist Baffles Novak Djokovic - HEAD Launches Trick Shot Campaign “Frame & Play” 2
... This release is available in French . ... the American Urology Association (AUA) in Washington, DC demonstrates that ... for Benign Prostatic Hyperplasia (BPH) an enlargement of the ... conducted by researchers from the McGill University Health Centre (MUHC), ...
... significant differences between new and old red blood cells ... and effective way to monitor the quality of blood ... in banks continues to age, resulting in biomaterials leaking ... cell properties and function. There have been concerns ...
... Reinberg HealthDay Reporter , THURSDAY, May 19 (HealthDay ... an road accident has been able to stand up by ... steps on a treadmill, thanks to electrical stimulation of his ... cord stimulation -- mimics signals the brain normally sends to ...
... Reporter , THURSDAY, May 19 (HealthDay News) -- The U.S. ... drug Avandia will no longer be sold at retail pharmacies ... to patients. According to the new rules, which will ... be available to patients who,ve been safely using the ...
... May 19 (HealthDay News) -- Hispanic women who suffer ... a fivefold increased risk of postpartum depression, U.S. researchers ... is a stronger predictor of postpartum depression than prenatal ... risk factor. The study of 210 Hispanic women ...
... The Children,s Health Insurance Program Reauthorization Act (CHIPRA) ... quality measures to be identified for voluntary use by ... which together cover almost 40 million American children and ... official journal of the American Pediatric Association, noted authorities ...
Cached Medicine News:Health News:Enlarged prostate: Study demonstrates immediate and long-term benefits of laser treatment 2Health News:Research provides insight into quality of stored blood used for transfusions 2Health News:Research provides insight into quality of stored blood used for transfusions 3Health News:Spinal Stimulation Helps Paralyzed Man Regain Movement 2Health News:Spinal Stimulation Helps Paralyzed Man Regain Movement 3Health News:Spinal Stimulation Helps Paralyzed Man Regain Movement 4Health News:FDA to Pull Diabetes Drug Avandia From Pharmacy Shelves 2Health News:FDA to Pull Diabetes Drug Avandia From Pharmacy Shelves 3Health News:Important info about CHIPRA core set of recommended health care quality measures released 2Health News:Important info about CHIPRA core set of recommended health care quality measures released 3Health News:Important info about CHIPRA core set of recommended health care quality measures released 4Health News:Important info about CHIPRA core set of recommended health care quality measures released 5
TOX/See is a 1-step, hand-held, point-of-care device for the qualitative detection of drug or drug metabolites in human urine....
Compact, bench-top analyser with minimal water volume requirements and easy waste management....
Compact benchtop clinical chemistry system...
... 350 Chemistry System offers easy operation, maintenance, and ... STAT, or back-up to the powerful VITROS 5,1 ... the job done right the first time. Its ... are efficient, dependable, and easy-to-use. The VITROS 350 ...
Medicine Products: